Zentalis Pharmaceuticals Inc Ordinary Shares ZNTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.61
- Day Range
- $2.50–2.65
- 52-Week Range
- $1.21–6.95
- Bid/Ask
- $2.48 / $2.52
- Shares Outstanding
- 98.12M
- Market Cap
- $238.57M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.65%
Company Profile
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 106
- Website
- https://www.zentalis.com
Valuation
|
Metric
|
ZNTL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ZNTL
|
|---|---|
Quick Ratio | 4.64 |
Current Ratio | 4.82 |
Interest Coverage | — |
Quick Ratio
ZNTL
Profitability
|
Metric
|
ZNTL
|
|---|---|
Return on Assets (Normalized) | −44.84% |
Return on Equity (Normalized) | −60.19% |
Return on Invested Capital (Normalized) | −51.60% |
Return on Assets
ZNTL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!JDzv@ | LOCK|P%xD& | $128B | |||
| Moderna Inc
MRNA
| LOCK|^LZz&# | LOCK|C? | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<&<d$t | LOCK|tDw% | $76B | |||
| argenx SE ADR
ARGX
| LOCK|^Y<b%%K | LOCK|$? | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|J@C?HB | LOCK|$# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Zv!?!N | LOCK|?CZM | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|l&?%<<b | LOCK|Jv%#? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?%#@d> | LOCK|ZfM | $24B | |||
| Incyte Corp
INCY
| LOCK|$fb%C< | LOCK|qFp | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>DGBZWq | LOCK|B&f | $15B |
United States